CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
The EMA has awarded orphan drug designation to GC Biopharma Corp.’s intracerebroventricular enzyme replacement therapy (ERT) candidate, GC-1130A, for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A), developed in collaboration with Novel Pharma Inc.
NK Celltech Co. Ltd. has announced FDA clearance for a clinical trial of NK-010, a nongenetically modified allogeneic peripheral blood natural killer (NK) cell drug.
Several highly pathogenic viruses, including SARS-CoV-2, share a conserved mechanism of infection via the fusion of the viral and host membranes employing a six-helix bundle (6-HB) heptad repeat.
Strand Therapeutics Inc. has received IND clearance from the FDA to initiate a first-in-human phase I trial of STX-001 as a new approach for the treatment of solid tumors.
Simultaneous inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway and histone deacetylase (HDAC) provides synergistic efficacy in the treatment of hematological malignancies.
The Kv1.1 potassium channel regulates neuronal excitability both in the central and peripheral nervous systems and its dysfunction is associated with epilepsy, among others.
Researchers from Universidade Federal de Minas Gerais have published details on the discovery of novel anti-SARS-CoV-2 compounds with robust antiviral activity.
Reithera Srl, The Ragon Institute of Mass General, MIT and Harvard, and IAVI have established a collaboration to develop a novel HIV vaccine candidate based on gorilla adenoviral vector (GRAd), with funding by the Bill & Melinda Gates Foundation.
RSS
